Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis
Authors: Rochelle P. Walensky, Tim Horn, Nicole C. McCann, Kenneth A. Freedberg, A. David Paltiel
Journal: Annals of Internal Medicine (2020)

Letters15 September 2020Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure ProphylaxisRochelle P. Walensky, MD, MPH, Tim Horn, MS, Nicole C. McCann, BA, Kenneth A. Freedberg, MD, MSc, and A. David Paltiel, MBA, PhDRochelle P. Walensky, MD, MPHMedical Practice Evaluation Center, Massachusetts General Hospital, Harvard University Center for AIDS Research, Harvard Medical School, Boston, Massachusetts (R.P.W.), Tim Horn, MSNational Alliance of State and Territorial AIDS Directors, Washington, DC (T.H.), Nicole C. McCann, BAMassachusetts General Hospital, Boston, Massachusetts (N.C.M.), Kenneth A. Freedberg, MD, MScMassachusetts General Hospital and Harvard University Center for AIDS Research, Harvard Medical School, Boston, Massachusetts (K.A.F.), and A. David Paltiel, MBA, PhDYale School of Public Health, New Haven, Connecticut (A.D.P.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-0693 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We would like to respond to each of the 7 critiques offered by Dr. Das and colleagues.First, the U.S. Panel on Cost-Effectiveness in Health and Medicine recommends using the health care sector and/or societal perspective but makes no mention of a patient perspective for purposes of economic evaluation (1). We conducted our analysis from a modified societal perspective. Although we excluded patient time costs, unpaid caregiver time costs, and transportation costs, each of these would have been similar for both F/TAF and F/TDF.Second, the speed of advances in HIV prevention justifies a 5-year time horizon. In ...References1. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316:1093-1103. [PMID: 27623463] doi:10.1001/jama.2016.12195 CrossrefMedlineGoogle Scholar2. Chou R, Evans C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;321:2214-2230. [PMID: 31184746] doi:10.1001/jama.2019.2591 CrossrefMedlineGoogle Scholar3. Walensky RP, Paltiel AD. PrEP school: a field manual for the battle over HIV prevention drug pricing. Health Affairs Blog. 29 August 2019. Accessed at www.healthaffairs.org/do/10.1377/hblog20190826.11005/full on 18 May 2019. Google Scholar Author, Article, and Disclosure InformationAffiliations: Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard University Center for AIDS Research, Harvard Medical School, Boston, Massachusetts (R.P.W.)National Alliance of State and Territorial AIDS Directors, Washington, DC (T.H.)Massachusetts General Hospital, Boston, Massachusetts (N.C.M.)Massachusetts General Hospital and Harvard University Center for AIDS Research, Harvard Medical School, Boston, Massachusetts (K.A.F.)Yale School of Public Health, New Haven, Connecticut (A.D.P.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-3478. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis Rochelle P. Walensky , Tim Horn , Nicole C. McCann , Kenneth A. Freedberg , and A. David Paltiel Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis Moupali Das , Jie Ting , Sanatan Shreay , and Staci Bush Metrics Cited byPerverse Incentives — HIV Prevention and the 340B Drug Pricing ProgramCost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States A Cost-Effectiveness AnalysisAnne M. Neilan, MD, MPH, Raphael J. Landovitz, MD, MSc, Mylinh H. Le, BA, Beatriz Grinsztejn, MD, PhD, Kenneth A. Freedberg, MD, MSc, Marybeth McCauley, MPH, Nattanicha Wattananimitgul, BA, Myron S. Cohen, MD, Andrea L. Ciaranello, MD, MPH, Meredith E. Clement, MD, Krishna P. Reddy, MD, MS, Emily P. Hyle, MD, MSc, A. David Paltiel, PhD, and Rochelle P. Walensky, MD, MPHSwitching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health CenterEvaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults 15 September 2020Volume 173, Issue 6Page: 507-508 ePublished: 15 September 2020 Issue Published: 15 September 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...